Aurora Cannabis Inc. (NASDAQ:ACB)

Aurora Cannabis Inc. ACB

Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - CA

Watchlist

$ 4.2

-3.23 %

$ 230 M

Market Cap

-8.75

P/E

1. INTRINSIC VALUE

Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers.[ Read More ]

The intrinsic value of one ACB stock under the base case scenario is HIDDEN Compared to the current market price of 4.2 USD, Aurora Cannabis Inc. is HIDDEN

ACB Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart ACB

FINANCIALS

Annual
Quarterly

270 M REVENUE

Growth Rates

1Year 15.86%

3Years 3.29%

5Years 1.74%

7Years 47.18%

10Years 0.00%

-46.5 M OPERATING INCOME

Growth Rates

1Year 81.73%

3Years 45.24%

5Years 31.77%

7Years -22.55%

10Years -65.22%

-59 M NET INCOME

Growth Rates

1Year 77.75%

3Years 56.01%

5Years 27.65%

7Years -24.18%

10Years -64.80%

-68.5 M OPERATING CASH FLOW

Growth Rates

1Year 40.85%

3Years 31.22%

5Years 18.65%

7Years -30.72%

10Years -85.79%

-5.49 M INVESTING CASH FLOW

Growth Rates

1Year 79.89%

3Years 41.14%

5Years 55.44%

7Years 27.17%

10Years -18.56%

-47.9 M FINANCING CASH FLOW

Growth Rates

1Year 15.15%

3Years -2.97%

5Years -1.55%

7Years -2.85%

10Years -43.04%

67.4 M REVENUE

Growth Rates

1Year 15.86%

3Years 3.29%

5Years 1.74%

7Years 47.18%

10Years 0.00%

3.15 M OPERATING INCOME

Growth Rates

1Year 81.73%

3Years 45.24%

5Years 31.77%

7Years -22.55%

10Years -65.22%

-13.3 M NET INCOME

Growth Rates

1Year 77.75%

3Years 56.01%

5Years 27.65%

7Years -24.18%

10Years -64.80%

-21.1 M OPERATING CASH FLOW

Growth Rates

1Year 40.85%

3Years 31.22%

5Years 18.65%

7Years -30.72%

10Years -85.79%

-6.24 M INVESTING CASH FLOW

Growth Rates

1Year 79.89%

3Years 41.14%

5Years 55.44%

7Years 27.17%

10Years -18.56%

-4.87 M FINANCING CASH FLOW

Growth Rates

1Year 15.15%

3Years -2.97%

5Years -1.55%

7Years -2.85%

10Years -43.04%

Balance Sheet Decomposition Aurora Cannabis Inc.

839 M ASSETS
237 M LIABILITIES

Current Assets	427 M
Cash & Short-Term Investments	117 M
Receivables	45.4 M
Other Current Assets	264 M
Non-Current Assets	412 M
Long-Term Investments	6.34 M
PP&E	294 M
Other Non-Current Assets	111 M

Current Liabilities	125 M
Accounts Payable	20.3 M
Short-Term Debt	57.2 M
Other Current Liabilities	47.1 M
Non-Current Liabilities	112 M
Long-Term Debt	47.6 M
Other Non-Current Liabilities	64.6 M

EFFICIENCY

Earnings Waterfall Aurora Cannabis Inc.

Revenue	270 M
Cost Of Revenue	139 M
Gross Profit	131 M
Operating Expenses	159 M
Operating Income	-46.5 M
Other Expenses	12.6 M
Net Income	-59 M

RATIOS

48.64% GROSS MARGIN

Averages

1Year 48.64%

3Years 10.21%

5Years 1.96%

7Years 21.88%

10Years 28.90%

-17.19% OPERATING MARGIN

Averages

1Year -17.19%

3Years -76.92%

5Years -104.42%

7Years -117.48%

10Years -120.33%

-25.65% NET MARGIN

Averages

1Year -25.65%

3Years -305.13%

5Years -477.02%

7Years -338.87%

10Years -284.15%

-12.38% ROE

Averages

1Year -12.38%

3Years -108.83%

5Years -102.89%

7Years -73.78%

10Years -86.67%

-8.27% ROA

Averages

1Year -8.27%

3Years -65.10%

5Years -68.17%

7Years -48.91%

10Years -44.79%

-6.93% ROIC

Averages

1Year -6.93%

3Years -22.37%

5Years -19.29%

7Years -15.28%

10Years -17.22%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Aurora Cannabis Inc.

Net Income	-59 M
Depreciation & Amortization	33.1 M
Capital Expenditures	-17 M
Stock-Based Compensation	12.7 M
Change in Working Capital	-15.6 M
Others	-70.7 M
Free Cash Flow	-85.5 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Aurora Cannabis Inc.

Wall Street analysts predict an average 1-year price target for ACB of $6.67 , with forecasts ranging from a low of $1 to a high of $11 .

ACB Lowest Price Target Wall Street Target

1 USD -76.19%

ACB Average Price Target Wall Street Target

6.67 USD 58.73%

ACB Highest Price Target Wall Street Target

11 USD 161.90%

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany.

5.61 USD

CGC

Undervalued 50.48%

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Cannabis Operations and Retail Operations segments.

0 USD

SNDL

Overvalued 100.00%

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States.

5.64 USD

CRON

Undervalued 180.75%

Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates.

0 USD

OGI

Overvalued 100.00%

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.

4.83 USD

TLRY

Undervalued 258.08%

6. Ownership

Insider Ownership Aurora Cannabis Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price

7. News

Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + The 'Undercovered' Dozen series highlights 12 lesser-covered stocks from the past week, aiming to spark ideas and discussions among retail investors. Veradigm Inc. is undervalued due to regulatory pressures, but has significant upside potential with strategic buyers potentially paying mid- or high-teens per share. Casey's General Stores has outperformed its peers and the S&P 500 due to its strategic positioning in rural areas and strong operational execution. seekingalpha.com - 21 hours ago

3 Marijuana Stocks For Today Watchlist The future of cannabis investing rests in the hands of politicians who may not have the industry's best interests at heart. Right now, the majority of marijuana stocks are feeling the impact of cannabis politics surrounding reform and regulatory issues. Each party, Republicans and Democrats, walks a different path to passing comprehensive reform and looking at the sector as a whole. marijuanastocks.com - 1 day ago

Aurora Cannabis: Buy The Election Overreaction Aurora Cannabis dropped over 10%, along with the broader cannabis market, due to concerns over U.S. election results. Despite this, Aurora has no U.S. cannabis operations and is unaffected. Aurora reported robust revenue growth, with a 29% YoY increase, driven by a 93% rise in international medical cannabis sales. The company re-affirmed positive free cash flow expectations for Q3 and demonstrated strong spending discipline, maintaining positive adjusted EBITDA for the 8th consecutive quarter. seekingalpha.com - 5 days ago

Cannabis stocks plunge after DeSantis, Griffin win Florida fight against weed legalization Amendment 3 – which would have legalized the recreational use of marijuana in the state's constitution – failed to receive the 60% support needed to pass under Florida law. nypost.com - 1 week ago

Aurora Cannabis Inc. (ACB) Beats Q2 Earnings and Revenue Estimates Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.50 per share a year ago. zacks.com - 1 week ago

Cannabis stocks tank as Florida votes against recreational marijuana Shares in cannabis stocks such as Trulieve Cannabis Corp. (CSE:TRUL), Curaleaf Hldgs Inc. (CSE:CURA, OTCQX:CURLF) and Verano Holdings Corp (CSE:VRNO, OTCQX:VRNOF) tanked after Florida rejected legalization of recreational marijuana. A ballot measure, known as Amendment 3, which would have allowed adults to possess up to three ounces of marijuana, failed to obtain the required 60% of support from voters yesterday. proactiveinvestors.com - 1 week ago

Aurora Cannabis Inc. (ACB) Q2 2025 Earnings Call Transcript Aurora Cannabis Inc. (NASDAQ:ACB ) Q2 2025 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Kevin Niland - Director, Strategic Finance and IR Miguel Martin - CEO Simona King - CFO Conference Call Participants Frederico Gomes - ATB Capital Markets Pablo Zuanic - Zuanic & Associates Operator Greetings and welcome to the Aurora Cannabis Inc. Second Quarter 2025 Results Conference Call. all participants will be in a listen-only mode and a question-and-answer session will follow the formal presentation. seekingalpha.com - 1 week ago

Aurora Cannabis Announces Fiscal 2025 Second Quarter Results NASDAQ | TSX: ACB Record Adjusted EBITDA1 of $10.1 Million, a YoY increase of 210% Quarterly Net Revenue1 up 29% YoY to $81.1 Million, with 41% growth in Global Medical Cannabis Re-Affirms Target of Positive Free Cash Flow1 in the Quarter Ending December 31, 2024 Maintains Strong Balance Sheet with ~$152 Million of Cash and a Debt-Free Cannabis Business2 EDMONTON, AB , Nov. 6, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter fiscal 2025. "Our strong quarterly results demonstrate Aurora's leadership in global medical cannabis and ability to capitalize on opportunities within rapidly growing markets such as Australia, Germany, Poland, and the UK. prnewswire.com - 1 week ago

Aurora Cannabis to Host Second Quarter 2025 Investor Conference Call NASDAQ | TSX: ACB EDMONTON, AB , Oct. 24, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today announced today that it has scheduled a conference call to discuss the results for its second quarter 2025 on Wednesday, November 6, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. prnewswire.com - 3 weeks ago

Aurora Cannabis Stock Rises Following Medical Cannabis Oil Launch ACB and MedReleaf Australia launch premium medical cannabis oils, offering tailored cannabinoid formulations for patient care. zacks.com - 1 month ago

Aurora Introduces Innovative Cannabis Oil Range to Meet Diverse Patient Needs in Australia NASDAQ | TSX: ACB Canada's Leading Medical Cannabis Company and MedReleaf Australia Launch New Oil Products for Enhanced Patient Care Options EDMONTON, AB , Oct. 16, 2024 /CNW/ - Aurora Cannabis Inc., (NASDAQ: ACB) (TSX: ACB) – the Canadian based global leader in medical cannabis, in conjunction with MedReleaf Australia, is pleased to announce an enhanced product range of premium medical cannabis oil in Australia. This expansion reinforces Aurora's dedication to providing high-quality, innovative cannabis solutions to patients around the world. prnewswire.com - 1 month ago

Is It Time to Load Up on Aurora Cannabis Stock? This Canadian pot stock has defied the broader downturn among its peer group in 2024. fool.com - 1 month ago

8. Profile Summary

Aurora Cannabis Inc. ACB

COUNTRY CA

INDUSTRY Drug Manufacturers - Specialty & Generic

MARKET CAP $ 230 M

Dividend Yield 0.00%

Description Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Contact 500 - 10355 Jasper Avenue, Edmonton, AB, T5J 1Y6 https://www.auroramj.com

IPO Date July 15, 2014

Employees 1073

Officers Mr. Miguel Martin Chief Executive Officer & Executive Chairman Mr. David Aird Executive Vice President of Information Technology Mr. Ananth Krishnan Vice President of Capital Markets & Investor Relations Ms. Lori Schick Executive Vice President of Human Resources Mr. Rick Savone Senior Vice President of Global Government Relations Michelle Lefler Vice President of Communications & Public Relations Mr. Andre Jerome Executive Vice President of Global Business Development Ms. Nathalie Clark Executive Vice President, General Counsel & Corporate Secretary Mr. Alex Miller Executive Vice President of Operations & Supply Chain Dr. Jonathan Page Ph.D. Senior Science Advisor

Price Chart ACB

Aurora Cannabis Inc. ACB

Premium Plan

Unlimited Plan